**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-20. Canceled

21. (previously presented) A compound of formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein:

A is -N(O-$C_1$-$C_6$ alkyl)-, -$CH_2$-, -$CH_2CH_2$-, or -CH=CH-;

$R_1$ is -halo, -$CH_3$, -$NO_2$, -CN, -OH, -$OCH_3$, -$NH_2$, -C(halo)$_3$, -CH(halo)$_2$, or -$CH_2$(halo);

each $R_2$ is independently:

(a) -halo, -CN, -OH, -$NO_2$, or -$NH_2$;

(b) -($C_1$-$C_{10}$)alkyl, -($C_2$-$C_{10}$)alkenyl, -($C_2$-$C_{10}$)alkynyl, -($C_3$-$C_{10}$)cycloalkyl, -($C_8$-$C_{14}$)bicycloalkyl, -($C_8$-$C_{14}$)tricycloalkyl, -($C_5$-$C_{10}$)cycloalkenyl, -($C_8$-$C_{14}$)bicycloalkenyl, -($C_8$-$C_{14}$)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more $R_5$ groups; or

(c) -phenyl, -naphthyl, -($C_{14}$)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more $R_6$ groups;

each $R_3$ is independently:

(a) -halo, -CN, -OH, -$NO_2$, or -$NH_2$;

(b) -($C_1$-$C_{10}$)alkyl, -($C_2$-$C_{10}$)alkenyl, -($C_2$-$C_{10}$)alkynyl, -($C_3$-$C_{10}$)cycloalkyl, -($C_8$-$C_{14}$)bicycloalkyl, -($C_8$-$C_{14}$)tricycloalkyl, -($C_5$-$C_{10}$)cycloalkenyl, -($C_8$-$C_{14}$)bicycloalkenyl, -($C_8$-$C_{14}$)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more $R_5$ groups; or

(c) -phenyl, -naphthyl, -($C_{14}$)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more $R_6$ groups;

$R_4$ is:

(a) -($C_1$-$C_{10}$)alkyl, -($C_2$-$C_{10}$)alkenyl, -($C_2$-$C_{10}$)alkynyl, -($C_3$-$C_{10}$)cycloalkyl, -($C_8$-$C_{14}$)bicycloalkyl, -($C_8$-$C_{14}$)tricycloalkyl, -($C_5$-$C_{10}$)cycloalkenyl, -($C_8$-$C_{14}$)bicycloalkenyl, -($C_8$-$C_{14}$)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more $R_5$ groups; or

(b) -phenyl, -naphthyl, -($C_{14}$)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more $R_6$ groups;

each $R_5$ is independently -CN, -OH, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -halo, -$N_3$, -$NO_2$, -$N(R_7)_2$, -CH=$NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -C(O)$OR_7$, -OC(O)$R_7$, -OC(O)$OR_7$, -$SR_7$, -S(O)$R_7$, or -$S(O)_2R_7$;

each $R_6$ is independently -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -$CH_2$(halo), -CN, -OH, -halo, -$N_3$, -$NO_2$, -$N(R_7)_2$, -CH=$NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -C(O)$OR_7$, -OC(O)$R_7$, -OC(O)$OR_7$, -$SR_7$, -S(O)$R_7$, or -$S(O)_2R_7$;

each $R_7$ is independently -H, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$ or -$CH_2$(halo);

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

22. (original) The compound of claim 21, wherein:

n is 0;

m is 0; and

$R_4$ is phenyl.

23. (original) The compound of claim 22, wherein the $R_4$ phenyl is unsubstituted.

24. (original) The compound of claim 22, wherein the $R_4$ phenyl is substituted at the 4-position.

25. (original) The compound of claim 24, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

26. (original) The compound of claim 25, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

27. (original) The compound of claim 25, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

28. (original) The compound of claim 24, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

29. (original) The compound of claim 24, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

30. (original) The compound of claim 21, wherein:

n is 0;

m is 1;

$R_3$ is methyl; and

$R_4$ is phenyl.

31. (original) The compound of claim 30, wherein the $R_4$ phenyl is unsubstituted.

32. (original) The compound of claim 30, wherein the $R_4$ phenyl is substituted at the 4-position.

33. (original) The compound of claim 32, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

34. (original) The compound of claim 33, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

35. (original) The compound of claim 33, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

36. (original) The compound of claim 32, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

37. (original) The compound of claim 32, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

38. (original) The compound of claim 21, wherein A is -N(O-$C_1$-$C_6$ alkyl)-.

39. (original) The compound of claim 21, wherein A is -$CH_2$-.

40. (original) The compound of claim 21, wherein A is -$CH_2CH_2$-.

41. (original) The compound of claim 21, wherein A is -CH=CH-.

42-61. Canceled

62. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

63-85. Canceled

86. (original) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

87. Canceled

88. (previously presented) A compound of formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein:

$Ar_2$ is


,

,

,

,


,

,

,


,

, or

;

$R_1$ is -H, -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each $R_2$ is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) -($C_1$-$C_{10}$)alkyl, -($C_2$-$C_{10}$)alkenyl, -($C_2$-$C_{10}$)alkynyl, -($C_3$-$C_{10}$)cycloalkyl, -($C_8$-$C_{14}$)bicycloalkyl, -($C_8$-$C_{14}$)tricycloalkyl, -($C_5$-$C_{10}$)cycloalkenyl, -($C_8$-$C_{14}$)bicycloalkenyl, -($C_8$-$C_{14}$)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more $R_5$ groups; or

(c) -phenyl, -naphthyl, -($C_{14}$)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more $R_6$ groups;

each $R_3$ is independently:

(a) -halo, -CN, -OH, -$NO_2$, or -$NH_2$;

(b) -($C_1$-$C_{10}$)alkyl, -($C_2$-$C_{10}$)alkenyl, -($C_2$-$C_{10}$)alkynyl, -($C_3$-$C_{10}$)cycloalkyl, -($C_8$-$C_{14}$)bicycloalkyl, -($C_8$-$C_{14}$)tricycloalkyl, -($C_5$-$C_{10}$)cycloalkenyl, -($C_8$-$C_{14}$)bicycloalkenyl, -($C_8$-$C_{14}$)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more $R_5$ groups; or

(c) -phenyl, -naphthyl, -($C_{14}$)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more $R_6$ groups;

each $R_5$ is independently -CN, -OH, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -halo, -$N_3$, -$NO_2$, -$N(R_7)_2$, -CH=$NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -C(O)$OR_7$, -OC(O)$R_7$, -OC(O)$OR_7$, -$SR_7$, -S(O)$R_7$, or -$S(O)_2R_7$;

each $R_6$ is independently -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -$CH_2$(halo), -CN, -OH, -halo, -$N_3$, -$NO_2$, -CH=$NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -C(O)$OR_7$, -OC(O)$R_7$, -OC(O)$OR_7$, -$SR_7$, -S(O)$R_7$, or -$S(O)_2R_7$;

each $R_7$ is independently -H, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -$CH_2$(halo);

each $R_8$ is independently -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -$CH_2$(halo);

each $R_9$ is independently -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$ $C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -C(halo)$_3$, -CH(halo)$_2$, -$CH_2$(halo), -CN, -OH, -halo, -$N_3$, -$NO_2$, -CH=$NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -C(O)$OR_7$, -OC(O)$R_7$, -OC(O)$OR_7$, -$SR_7$, -S(O)$R_7$, or -$S(O)_2R_7$;

each $R_{11}$ is independently -CN, -OH, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -halo, -$N_3$, -$NO_2$, -$N(R_7)_2$, -CH=$NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -C(O)$OR_7$, -OC(O)$R_7$, -OC(O)$OR_7$, -$SR_7$, -S(O)$R_7$, or -$S(O)_2R_7$;

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2;

m is 0 or 1;

o is an integer ranging from 0 to 4;

q is an integer ranging from 0 to 6;

r is an integer ranging from 0 to 5;

s is an integer ranging from 0 to 4; and

t is an integer ranging from 0 to 2.

89. (previously presented) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 88 and a pharmaceutically acceptable carrier or excipient.

90-98. Canceled

99. (previously presented) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 88 and a pharmaceutically acceptable carrier or excipient.

100. (previously presented) A compound of formula (V):




(V)

or a pharmaceutically acceptable salt thereof, wherein:

$Ar_2$ is



,


,


,


,



,


,


,



,


, or


;

$R_1$ is -H, -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each $R_2$ is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more $R_5$ groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more $R_6$ groups;

each $R_3$ is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-

membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more $R_5$ groups; or

(c) -phenyl, -naphthyl, -($C_{14}$)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more $R_6$ groups;

each $R_5$ is independently -CN, -OH, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -halo, -$N_3$, -$NO_2$, -$N(R_7)_2$, -CH=$NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -C(O)$OR_7$, -OC(O)$R_7$, -OC(O)$OR_7$, -$SR_7$, -S(O)$R_7$, or -$S(O)_2R_7$;

each $R_6$ is independently -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -$CH_2$(halo), -CN, -OH, -halo, -$N_3$, -$NO_2$, -CH=$NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -C(O)$OR_7$, -OC(O)$R_7$, -OC(O)$OR_7$, -$SR_7$, -S(O)$R_7$, or -$S(O)_2R_7$;

each $R_7$ is independently -H, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -$CH_2$(halo);

each $R_8$ is independently -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -$CH_2$(halo);

each $R_9$ is independently -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$ $C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -C(halo)$_3$, -CH(halo)$_2$, -$CH_2$(halo), -CN, -OH, -halo, -$N_3$, -$NO_2$, -CH=$NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -C(O)$OR_7$, -OC(O)$R_7$, -OC(O)$OR_7$, -$SR_7$, -S(O)$R_7$, or -$S(O)_2R_7$;

each $R_{11}$ is independently -CN, -OH, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -halo, -$N_3$, -$NO_2$, -$N(R_7)_2$, -CH=$NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -C(O)$OR_7$, -OC(O)$R_7$, -OC(O)$OR_7$, -$SR_7$, -S(O)$R_7$, or -$S(O)_2R_7$;

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2;

m is 0 or 1;

o is an integer ranging from 0 to 4;

q is an integer ranging from 0 to 6;

r is an integer ranging from 0 to 5;

s is an integer ranging from 0 to 4; and

t is an integer ranging from 0 to 2.

101. (previously presented) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 100 and a pharmaceutically acceptable carrier or excipient.

102-110. Canceled

111. (previously presented) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 100 and a pharmaceutically acceptable carrier or excipient.

112. (currently amended) ~~The~~ A compound of **formula (I)** ~~claim 1, wherein~~:



**(I)**

**or a pharmaceutically acceptable salt thereof, wherein:**

**A is -NH-, -N($C_1$-$C_6$)alkyl-, or -N-(O-$C_1$-$C_6$ alkyl)-;**

n is 0;

m is 1;

$R_3$ is -$CH_3$;

$R_1$ is -halo; ~~and~~

$R_4$ is phenyl **which is unsubstituted or substituted with one or more $R_6$ groups;**

**each $R_6$ is independently -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -$CH_2$(halo), -CN, -OH, -halo, -$N_3$, -$NO_2$, -N($R_7$)$_2$, -CH=N$R_7$, -N$R_7$OH, -O$R_7$, -COR$_7$, -C(O)O$R_7$, -OC(O)$R_7$, -OC(O)O$R_7$, -S$R_7$, -S(O)$R_7$, or -S(O)$_2$$R_7$;**

**each $R_7$ is independently -H, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -$CH_2$(halo); and**

**each halo is independently -F, -Cl, -Br, or -I.**

113. (original) The compound of claim 112, wherein the $R_4$ phenyl is unsubstituted.

114. (original) The compound of claim 112, wherein the $R_4$ phenyl is substituted at the 4-position.

115. (original) The compound of claim 114, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

116. (original) The compound of claim 115, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

117. (original) The compound of claim 115, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

118. (previously presented) The compound of claim 114, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

119. (previously presented) The compound of claim 114, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

120. (original) The compound of claim 112, wherein $R_1$ is -Cl.

121. (original) The compound of claim 120, wherein the $R_4$ phenyl is unsubstituted.

122. (original) The compound of claim 120, wherein the $R_4$ phenyl is substituted at the 4-position.

123. (original) The compound of claim 122, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

124. (original) The compound of claim 123, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

125. (original) The compound of claim 123, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

126. (previously presented) The compound of claim 122, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

127. (previously presented) The compound of claim 122, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

128. (original) The compound of claim 112, wherein $R_1$ is -F.

129. (original) The compound of claim 128, wherein the $R_4$ phenyl is unsubstituted.

130. (original) The compound of claim 128, wherein the $R_4$ phenyl is substituted at the 4-position.

131. (original) The compound of claim 130, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

132. (original) The compound of claim 131, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

133. (original) The compound of claim 131, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

134. (previously presented) The compound of claim 130, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

135. (previously presented) The compound of claim 130, wherein the $R_4$ phenyl is substituted with a $-OCF_3$ group.

136. (currently amended) ~~The~~ A compound of formula (I) ~~claim 1, wherein~~:



(I)

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH-, $-N(C_1-C_6)$alkyl-, or $-N-(O-C_1-C_6$ alkyl)-;

n is 0;

m is 1;

$R_3$ is $-CH_3$;

$R_1$ is $-CH_3$; ~~and~~

$R_4$ is phenyl which is unsubstituted or substituted with one or more $R_6$ groups;

each $R_6$ is independently $-(C_1-C_6)$alkyl, $-(C_2-C_6)$alkenyl, $-(C_2-C_6)$alkynyl, $-(C_3-C_8)$cycloalkyl, $-(C_5-C_8)$cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, $-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)$, -CN, -OH, -halo, $-N_3$, $-NO_2$, $-N(R_7)_2$, $-CH=NR_7$, $-NR_7OH$, $-OR_7$, $-COR_7$, $-C(O)OR_7$, $-OC(O)R_7$, $-OC(O)OR_7$, $-SR_7$, $-S(O)R_7$, or $-S(O)_2R_7$;

each $R_7$ is independently -H, $-(C_1-C_6)$alkyl, $-(C_2-C_6)$alkenyl, $-(C_2-C_6)$alkynyl, $-(C_3-C_8)$cycloalkyl, $-(C_5-C_8)$cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$; and

each halo is independently -F, -Cl, -Br, or -I.

137. (original) The compound of claim 136, wherein the $R_4$ phenyl is unsubstituted.

138. (original) The compound of claim 136, wherein the $R_4$ phenyl is substituted at the 4-position.

139. (original) The compound of claim 138, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

140. (original) The compound of claim 139, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

141. (original) The compound of claim 139, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

142. (previously presented) The compound of claim 138, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

143. (previously presented) The compound of claim 138, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

144. (original) The compound of claim 21, wherein:

n is 0;

m is 1;

$R_3$ is -$CH_3$;

$R_1$ is -halo; and

$R_4$ is phenyl.

145. (original) The compound of claim 144, wherein the $R_4$ phenyl is unsubstituted.

146. (original) The compound of claim 144, wherein the $R_4$ phenyl is substituted at the 4-position.

147. (original) The compound of claim 146, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

148. (original) The compound of claim 147, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

149. (original) The compound of claim 147, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

150. (previously presented) The compound of claim 146, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

151. (previously presented) The compound of claim 146, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

152. (original) The compound of claim 144, wherein $R_1$ is -Cl.

153. (original) The compound of claim 152, wherein the $R_4$ phenyl is unsubstituted.

154. (original) The compound of claim 152, wherein the $R_4$ phenyl is substituted at the 4-position.

155. (original) The compound of claim 154, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

156. (original) The compound of claim 155, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

157. (original) The compound of claim 155, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

158. (previously presented) The compound of claim 154, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

159. (previously presented) The compound of claim 154, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

160. (original) The compound of claim 144, wherein $R_1$ is -F.

161. (original) The compound of claim 160, wherein the $R_4$ phenyl is unsubstituted.

162. (original) The compound of claim 160, wherein the $R_4$ phenyl is substituted at the 4-position.

163. (original) The compound of claim 162, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

164. (original) The compound of claim 163, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

165. (original) The compound of claim 163, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

166. (previously presented) The compound of claim 162, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

167. (previously presented) The compound of claim 162, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

168. (original) The compound of claim 21, wherein:

n is 0;

m is 1;

$R_1$ is -$CH_3$; and

$R_4$ is phenyl.

169. (original) The compound of claim 168, wherein the $R_4$ phenyl is unsubstituted.

170. (original) The compound of claim 168, wherein the $R_4$ phenyl is substituted at the 4-position.

171. (original) The compound of claim 170, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

172. (original) The compound of claim 171, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

173. (original) The compound of claim 171, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

174. (previously presented) The compound of claim 170, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

175. (previously presented) The compound of claim 170, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

176. (currently amended) ~~The~~ A compound of **formula (III)** ~~claim 1, wherein~~:



**(III)**

**or a pharmaceutically acceptable salt thereof, wherein:**

**A is -NH- or -N($C_1$-$C_6$)alkyl-;**

n is 0;

m is 1;

$R_3$ is -$CH_3$;

$R_1$ is -halo; ~~and~~

$R_4$ is phenyl **which is unsubstituted or substituted with one or more $R_6$ groups;**

**each $R_6$ is independently -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -$CH_2$(halo), -CN, -OH, -halo, -$N_3$, -$NO_2$, -$N(R_7)_2$, -$CH{=}NR_7$, -$NR_7$OH, -$OR_7$, -$COR_7$, -$C(O)OR_7$, -$OC(O)R_7$, -$OC(O)OR_7$, -$SR_7$, -$S(O)R_7$, or -$S(O)_2R_7$;**

**each $R_7$ is independently -H, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -$CH_2$(halo); and**

**each halo is independently -F, -Cl, -Br, or -I**.

177. (original) The compound of claim 176, wherein the $R_4$ phenyl is unsubstituted.

178. (original) The compound of claim 176, wherein the $R_4$ phenyl is substituted at the 4-position.

179. (original) The compound of claim 178, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

180. (original) The compound of claim 179, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

181. (original) The compound of claim 179, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

182. (previously presented) The compound of claim 178, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

183. (previously presented) The compound of claim 178, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

184. (original) The compound of claim 176, wherein $R_1$ is -Cl.

185. (original) The compound of claim 184, wherein the $R_4$ phenyl is unsubstituted.

186. (original) The compound of claim 184, wherein the $R_4$ phenyl is substituted at the 4-position.

187. (original) The compound of claim 186, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

188. (original) The compound of claim 187, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

189. (original) The compound of claim 187, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

190. (previously presented) The compound of claim 186, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

191. (previously presented) The compound of claim 186, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

192. (original) The compound of claim 176, wherein $R_1$ is -F.

193. (original) The compound of claim 192, wherein the $R_4$ phenyl is unsubstituted.

194. (original) The compound of claim 192, wherein the $R_4$ phenyl is substituted at the 4-position.

195. (original) The compound of claim 194, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

196. (original) The compound of claim 195, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

197. (original) The compound of claim 195, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

198. (previously presented) The compound of claim 194, wherein the $R_4$ phenyl is substituted with a $-CF_3$ group.

199. (previously presented) The compound of claim 194, wherein the $R_4$ phenyl is substituted with a $-OCF_3$ group.

200. (currently amended) ~~The~~ A compound of **formula (III)** ~~claim 1, wherein~~:



**(III)**

**or a pharmaceutically acceptable salt thereof, wherein:**

**A is -NH- or -N($C_1$-$C_6$)alkyl-;**

n is 0;

m is 1;

$R_3$ is $-CH_3$;

$R_1$ is $-CH_3$; ~~and~~

$R_4$ is phenyl **which is unsubstituted or substituted with one or more $R_6$ groups;**

**each $R_6$ is independently -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, $-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)$, -CN, -OH, -halo, $-N_3$, $-NO_2$, $-N(R_7)_2$, $-CH{=}NR_7$, $-NR_7OH$, $-OR_7$, $-COR_7$, $-C(O)OR_7$, $-OC(O)R_7$, $-OC(O)OR_7$, $-SR_7$, $-S(O)R_7$, or $-S(O)_2R_7$;**

**each $R_7$ is independently -H, -($C_1$-$C_6$)alkyl, -($C_2$-$C_6$)alkenyl, -($C_2$-$C_6$)alkynyl, -($C_3$-$C_8$)cycloalkyl, -($C_5$-$C_8$)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$; and**

**each halo is independently -F, -Cl, -Br, or -I.**

201. (original) The compound of claim 200, wherein the $R_4$ phenyl is unsubstituted.

202. (original) The compound of claim 200, wherein the $R_4$ phenyl is substituted at the 4-position.

203. (original) The compound of claim 202, wherein the $R_4$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

204. (original) The compound of claim 203, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

205. (original) The compound of claim 203, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

206. (previously presented) The compound of claim 202, wherein the $R_4$ phenyl is substituted with a -$CF_3$ group.

207. (previously presented) The compound of claim 202, wherein the $R_4$ phenyl is substituted with a -$OCF_3$ group.

208. (new) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 112 and a pharmaceutically acceptable carrier or excipient.

209. (new) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 112 and a pharmaceutically acceptable carrier or excipient.

210. (new) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 136 and a pharmaceutically acceptable carrier or excipient.

211. (new) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 136 and a pharmaceutically acceptable carrier or excipient.

212. (new) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 176 and a pharmaceutically acceptable carrier or excipient.

213. (new) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 176 and a pharmaceutically acceptable carrier or excipient.

214. (new) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 200 and a pharmaceutically acceptable carrier or excipient.

215. (new) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 200 and a pharmaceutically acceptable carrier or excipient.

216. (new) The compound of claim 88, wherein:

n is 0;

t is 0;

m is 0; and

$Ar_2$ is phenyl.

217. (new) The compound of claim 216, wherein the $Ar_2$ phenyl is unsubstituted.

218. (new) The compound of claim 216, wherein the $Ar_2$ phenyl is substituted at the 4-position.

219. (new) The compound of claim 218, wherein the $Ar_2$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

220. (new) The compound of claim 219, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

221. (new) The compound of claim 219, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

222. (new) The compound of claim 218, wherein the $Ar_2$ phenyl is substituted with a -$CF_3$ group.

223. (new) The compound of claim 218, wherein the $Ar_2$ phenyl is substituted with a -$OCF_3$ group.

224. (new) The compound of claim 88, wherein:

n is 0;

t is 0;

m is 1;

$R_3$ is methyl; and

$Ar_2$ is phenyl.

225. (new) The compound of claim 224, wherein the $Ar_2$ phenyl is unsubstituted.

226. (new) The compound of claim 224, wherein the $Ar_2$ phenyl is substituted at the 4-position.

227. (new) The compound of claim 226, wherein the $Ar_2$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

228. (new) The compound of claim 227, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

229. (new) The compound of claim 227, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

230. (new) The compound of claim 226, wherein the $Ar_2$ phenyl is substituted with a -$CF_3$ group.

231. (new) The compound of claim 226, wherein the $Ar_2$ phenyl is substituted with a $-OCF_3$ group.

232. (new) The compound of claim 100, wherein:

n is 0;

t is 0;

m is 0; and

$Ar_2$ is phenyl.

233. (new) The compound of claim 232, wherein the $Ar_2$ phenyl is unsubstituted.

234. (new) The compound of claim 232, wherein the $Ar_2$ phenyl is substituted at the 4-position.

235. (new) The compound of claim 234, wherein the $Ar_2$ phenyl is substituted with a $-(C_1-C_6)$ alkyl group.

236. (new) The compound of claim 235, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.

237. (new) The compound of claim 235, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

238. (new) The compound of claim 234, wherein the $Ar_2$ phenyl is substituted with a $-CF_3$ group.

239. (new) The compound of claim 234, wherein the $Ar_2$ phenyl is substituted with a $-OCF_3$ group.

240. (new) The compound of claim 100, wherein:

n is 0;

t is 0;

m is 1;

$R_3$ is methyl; and

$Ar_2$ is phenyl.

241. (new) The compound of claim 240, wherein the $Ar_2$ phenyl is unsubstituted.

242. (new) The compound of claim 240, wherein the $Ar_2$ phenyl is substituted at the 4-position.

243. (new) The compound of claim 242, wherein the $Ar_2$ phenyl is substituted with a -($C_1$-$C_6$) alkyl group.

244. (new) The compound of claim 243, wherein the -($C_1$-$C_6$) alkyl group is a *tert*-butyl group.

245. (new) The compound of claim 243, wherein the -($C_1$-$C_6$) alkyl group is an *iso*-propyl group.

246. (new) The compound of claim 242, wherein the $Ar_2$ phenyl is substituted with a -$CF_3$ group.

247. (new) The compound of claim 242, wherein the $Ar_2$ phenyl is substituted with a -$OCF_3$ group.